1. SP0143 A new day for people with psoriatic arthritis: a heterogeneous disease that can be treated well?. (15th June 2017) Authors: Coates, LC Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 35 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FRI0479 Predictors of long-term modified minimal disease activity response in peripheral spondyloarthritis patients treated with adalimumab. (15th June 2017) Authors: Coates, LC; Abraham, S; Tillett, W; Mease, PJ; Ramiro, S; Wu, T; Wang, X; Pangan, AL; Song, I-H Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 668 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. FRI0521 Secukinumab provides sustained improvements in work productivity and health related quality of life in patients with active psoriatic arthritis: 2-year results from future 1 and future 2. (15th June 2017) Authors: Strand, V; FitzGerald, O; Coates, LC; Walsh, JA; Cañete, JD; Bhosekar, V; Pricop, L; Gandhi, K; Jugl, S Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 688 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. FRI0502 Ixekizumab reduces disease activity in active psoriatic arthritis patients who had previous inadequate response to tumour necrosis factor-inhibitors. (15th June 2017) Authors: Coates, LC; Mease, P; Husni, ME; Lespessailles, E; Adams, DH; Benichou, O; Kerr, L; Helliwell, P Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 679 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. SAT0462 Secukinumab provides sustained pasdas related low disease activity in psoriatic arthritis: 2 year results from the future 2 study. (15th June 2017) Authors: Coates, LC; Gladman, DD; Nash, P; Fitzgerald, O; Kavanaugh, A; Rasouliyan, L; Pricorp, L; Ding, K; Gaillez, C Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 948 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. SAT0464 The ideal target for psoriatic arthritis? comparison of remission and inactive disease states in a real life cohort. (15th June 2017) Authors: Mens, LJJ Van; Kuijk, AWR van; Baeten, DL; Coates, LC Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 949 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. OP0108 Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity. (15th June 2017) Authors: Landewé, R; Ritchlin, CT; Coates, LC; Aletaha, D; Guérette, B; Zhang, Y; Ganz, F; Hojnik, M Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 97 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. FRI0503 Validation of new potential targets for remission in psoriatic arthritis in patients treated with golimumab. (15th June 2017) Authors: Coates, LC; Rahman, P; Psaradellis, E; Karellis, A; Rampakakis, E; Osborne, B; Tkaczyk, C; Lehman, AJ; Nantel, F Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 679 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. AB0772 Secukinumab provides sustained improvement in function, quality of life and fatigue over 2 years in patients who achieved low disease activity related to psoriatic arthritis disease activity score (PASDAS). (15th June 2017) Authors: Coates, LC; Kvien, TK; Nash, P; Gossec, L; Strand, V; Pricop, L; Rasouliyan, L; Ding, K; Jugl, S; Gaillez, C Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 1326 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. SAT0469 Integrated efficacy analysis of tofacitinib, an oral janus kinase inhibitor, in patients with active psoriatic arthritis. (15th June 2017) Authors: Nash, P; Coates, LC; Fleischmann, R; Papp, KA; Gomez-Reino, JJ; Kanik, KS; Wang, C; Wu, J; Hendrikx, T; Ports, WC Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 951 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗